MedTrace Logo

Optimization of Glycemic Control in the Hospital and Critical Care Setting

NCT04015388 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2021-02-11

No results posted yet for this study

Summary

Continuous Glucose Monitoring collected using the iPro device, to complete a large dataset consisting of routine electronic health records, biological, neurophysiological, physiological, and glycemic data. This dataset will eventually contribute to the further development and optimization of a comprehensive simulation, training, and clinical decision support system designed to contribute the optimization of glycemic control in the hospital and critical care setting.

Conditions

Interventions

DEVICE

iPro Continuous Glucose Monitoring

iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Ravi Tripathi, MD · Ohio State University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-19
Primary Completion
2016-08-02
Completion
2021-02-04
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04015388 on ClinicalTrials.gov